LifeActive Bio, an innovative biomaterials company, has officially emerged from stealth mode, unveiling a transformative approach to therapeutic delivery with its Molecular Administration Platform™ (MAP). This breakthrough technology redefines how pharmaceutical and nutritional elements are delivered in the human body. 

MAP is a natural lipo-surfactant microemulsion that dynamically encapsulates active molecules, delivering them through the skin into systemic circulation. Utilizing ingredients recognized as Generally Recognized as Safe (GRAS) by the FDA, MAP bypasses first-pass metabolism, ensuring safe, efficient, and targeted delivery of both new and existing compounds. 

What sets LifeActive Bio’s MAP apart is its unique capability to support polypharmacy and parenteral multi-nutrient delivery applications. Unlike conventional platforms, MAP enables the transport of larger molecules through the skin with molecular weights up to 1000 g/mol, three times the traditionally accepted 300 g/mol limit. This innovative approach opens new pathways in health and wellness by making therapeutic delivery safer, more precise, and metabolically beneficial. 

“With MAP, we’re paving the way for new therapeutic possibilities and establishing a novel standard for delivery in health and wellness,” said Dex Morris, CEO of LifeActive Bio. “We’re excited to embark on this journey to make a meaningful impact on lives worldwide through cutting-edge biotechnology.“ 

As LifeActive Bio begins its mission to advance health and wellness through its proprietary technology, it invites healthcare professionals, investors, and industry leaders to learn more about MAP and join in shaping the future of therapeutic delivery.